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FORM OVER SUBSTANCE: THE INADEQUACY OF 
INFORMED CONSENT AND ETHICAL REVIEW FOR 
THAI INJECTION DRUG USERS ENROLLED IN HIV 
VACCINE TRIALS 
Joan M. Doherty† 
Abstract:  Acquired Immune Deficiency Syndrome (“AIDS”) has emerged as a 
health issue of global significance, and clinical research on Human Immunodeficiency 
Virus (“HIV”) and AIDS has become increasingly international in scope.  A clinical trial 
of a vaccine designed to prevent the spread of the HIV raises important legal and ethical 
questions because injection drug users who were believed to be unsuitable subjects for 
study in the United States were singled out for research in Thailand.  The protections for 
human subjects must not be compromised when U.S. pharmaceutical companies conduct 
research abroad, particularly where clinical trials are conducted in vulnerable 
populations.   
U.S. regulations, as well as international declarations and guidelines, require two 
primary protections for research subjects: individual voluntary informed consent, and 
prior review of proposed research by an independent ethical review committee.  Ethical 
review committees should gauge the adequacy of informed consent by the substance of 
the information communicated between researcher and participant, and should not be 
satisfied with a mere signature on a consent form.  The recent clinical trial of HIV 
vaccines in the United States and Thailand highlights the gaps and weaknesses in the 
current system of protections for human subjects.  Members of the committees that 
reviewed the protocols for the AIDSVAX vaccine failed to properly consider the 
vulnerability of the subject population and the implications for informed consent. 
Countries that host research sponsors, as well as countries that host research 
volunteers, must share the responsibility of protecting human subjects.  To strengthen the 
protections for human subjects, Thailand should enact comprehensive national 
legislation, and existing legislative protections in the United States should be expanded to 
reflect the increasingly international scope of biomedical research.  As a case study, the 
AIDSVAX clinical trials can provide useful information for planning more equitable HIV 
vaccine trials in the future. 
I. INTRODUCTION 
Acquired Immune Deficiency Syndrome (“AIDS”) has become a 
health epidemic that no community, nation, or continent can ignore.  AIDS is 
the “first modern infectious disease to strike the developed and developing 
world simultaneously and to give both a large stake in finding a cure.”1  As 
biomedical research becomes increasingly international in scope, clinical 
trials often involve several nations that are socially, politically, and 
                                           
†
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1
  David J. Rothman, The Shame of Medical Research, N.Y. REV. OF BOOKS, Nov. 30, 2000, at 60-
64. 
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economically distinct.2  When clinical research is conducted in both 
developed and developing nations, a system of protections is necessary to 
ensure that the treatment of human subjects does not vary with the location 
of the research. 
Federal regulations in the United States and most international 
guidelines require two fundamental protections for research subjects: (1) 
individual voluntary informed consent, and (2) prior review of proposed 
research by an independent ethical review committee.3  These protections 
are necessary to ensure that the autonomy of research participants is 
respected, that volunteers consider the risks and benefits of participation, 
and that the benefits and burdens of research are equitably distributed.4  
A recent clinical trial of a vaccine designed to prevent the spread of 
Human Immunodeficiency Virus (“HIV”) raises important legal and ethical 
questions because injection drug users who were believed to be unsuitable 
subjects for study in the United States were singled out for research in 
Thailand.5  At the time of the research, injection drug users were subjected to 
coercive government programs in Thailand that did not exist in the United 
States.6  Given the study populations and social conditions in Thailand at the 
time of the study, it would have been more appropriate to conduct the 
research solely in the United States.  When protocol review committees 
slavishly adhere to regulatory forms without properly considering 
substantive ethical issues and the local research context, inappropriate 
research may proceed.  Approval by ethical review committees of HIV 
vaccine trials in Thailand represents one example of the form of legal and 
ethical analysis prevailing over substance.  
If the United States and Thailand continue to collaborate in the search 
for an HIV vaccine, the protections for human subjects that are enforced in 
the United States must be equally robust when applied in Thailand.  Part II 
of this Comment provides background information on the HIV clinical trials, 
and considers the ethical and legal implications of international biomedical 
research.  Part III argues that U.S. regulations provide one source of 
protection to human subjects in Thailand, given the absence of Thai 
                                           
2
   See Esther Chang, Fitting a Square Peg into a Round Hole?: Imposing Informed Consent and Post-
trial Obligations on United States Sponsored Clinical Trials in Developing Countries, 11 S. CAL. 
INTERDISC. L.J. 339, 340 (2002). 
3
  Ezekiel J. Emanuel et al., Oversight of Human Participants Research: Identifying Problems to 
Evaluate Reform Proposals, 141 ANNALS OF INTERNAL MED. 282, 282 (2004). 
4
   See Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research, 44 Fed. Reg. 23,192, 23,293-94 (Apr. 18, 1979), available at http://www.nihtraining.com/ 
ohsrsite/guidelines/belmont.html [hereinafter Belmont Report].   
5
  See discussion infra Part II.A. 
6
  See discussion infra Part IV.A.3. 
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legislation.  However, Part IV illustrates that in the case of the HIV vaccine 
clinical trials in Thailand, U.S. regulations governing informed consent were 
ineffectively applied.  Part V suggests several approaches to strengthen 
existing protections for human subjects in future clinical trials.  
II. INTERNATIONAL VACCINE TRIALS ADVANCE THE FIGHT AGAINST THE 
HIV/AIDS EPIDEMIC BUT ALSO HIGHLIGHT RESOURCE DISPARITIES 
Vaccines represent one possible way to curb the spread of HIV/AIDS. 
Most vaccines currently being explored in the context of HIV are preventive 
vaccines, which teach the body to recognize and defend itself against the 
viruses that cause the disease.7  Preventive vaccines cannot cure someone 
who has HIV or AIDS, but may prevent infection or slow the progression of 
HIV to AIDS.8  Clinical trials of vaccines are research studies in which new 
therapies for AIDS and HIV infection are tested in humans to assess whether 
the drugs or vaccines actually work as intended.9  Clinical trials of HIV 
vaccines progress through three phases.  After a vaccine is shown to be safe 
in humans at a particular dosage level (Phase I), and initial evidence shows 
that it might be effective (Phase II), it may proceed to large-scale efficacy 
trials (Phase III).10  
This Comment focuses on the challenges of conducting a Phase III 
HIV vaccine clinical trial.  First, HIV clinical trials require healthy 
volunteers.  In the typical research scenario, the subjects recruited for drug 
trials are directly interested in the outcome of the trial because they already 
have the disease the drug is designed to treat.11   Yet in order to know if a 
vaccine works, the subjects recruited for clinical trials must be healthy 
individuals who may be at risk for HIV at some future time.12  A second 
challenge for Phase III vaccine trials is the large number of volunteers 
needed.  While Phases I and II of vaccine testing require only several 
                                           
7
   See INTERNATIONAL AIDS VACCINE INITIATIVE, Questions and Answers About Vaccines & AIDS 
(2005), http://www.iavi.org/viewpage.cfm?aid=33.  
8
   Id. 
9
  See AIDSINFO, U.S. Department of Health and Human Services, What is an AIDS Clinical Trial?, 
(2005), http://www.aidsinfo.nih.gov/other/whatisct.pdf.  
10
  See Carol Rados, Inside Clinical Trials: Testing Medical Products in People, FDA CONSUMER, 
Sept.-Oct. 2003, available at http://www.fda.gov/fdac/features/2003/503_trial.html.  In the United States, a 
new vaccine must pass through four stages before it will be approved and licensed by the FDA. Testing 
vaccines in humans can only be undertaken after animal testing demonstrates that the vaccine is sufficiently 
safe, as determined by the FDA.  Jennifer Berman, Using the Doctrine of Informed Consent to Improve 
HIV Vaccine Access in the Post-TRIPS Era, 22 WIS. INT’L L. J. 273, 283 (2004). 
11
  See CHRISTINE GRADY, THE SEARCH FOR AN AIDS VACCINE: ETHICAL ISSUES IN THE 
DEVELOPMENT AND TESTING OF A PREVENTIVE HIV VACCINE 64-65 (1995). 
12
  Id. at 65.  
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hundred volunteers, Phase III trials test thousands of healthy participants for 
efficacy and side effects in order to reveal the less common effects of the 
vaccine.13  In particular, HIV vaccine trials require larger numbers of 
participants because only a small number of those vaccinated will ever be 
exposed to and contract HIV, even if no effective vaccine is given.14  In other 
words, for the clinical trials to be scientifically meaningful, the research 
subjects must not only be healthy, but must also have a relatively high risk of 
acquiring HIV.15  Phase III vaccine trials therefore pose the challenge of 
recruiting and maintaining a large number of healthy but at-risk volunteers.   
A. Participation Criteria for the VaxGen HIV Clinical Trials in Thailand 
Differed from the Criteria in the United States  
VaxGen, a biomedical research company based in the United States, 
developed an HIV vaccine called “AIDSVAX.”16  VaxGen also funded most 
aspects of the clinical trials to test the HIV vaccine.17  AIDSVAX was the 
first experimental vaccine to be approved by the Food and Drug 
Administration (“FDA”) for large-scale testing,18 and Thailand was the first 
developing nation to host a large human trial of an experimental HIV 
vaccine.19  The study began in the United States in June 1998,20 and in 
Bangkok, Thailand in March 1999.21  The Bangkok Metropolitan 
Administration (BMA) led the Thai trial, in conjunction with VaxGen, the 
Mahidol University Faculty of Tropical Medicine in Bangkok, and the 
HIV/AIDS Collaboration (a research collaborative between the Thai 
Ministry of Public Health and the Centers for Disease Control and 
Prevention).22  
Although the vaccine trials in the United States and Thailand tested 
similar versions of the AIDSVAX vaccine and were funded by the same 
company (VaxGen), there were significant differences in the criteria for 
                                           
13
  See Rados, supra note 10. 
14
  See Grady, supra note 11. 
15
  Id. at 121.  
16
  VaxGen is based in California.  AIDSINFO, U.S. Department of Health and Human Services, 
Questions and Answers on the Thailand Phase III Vaccine Study and CDC’s Collaboration (1999), 
http://aidsinfo.nih.gov/aprs/aprs_press.asp?an=A00487 [hereinafter AIDSINFO Phase III].  
17
  Id. “There’s no guarantee the vaccine will work, and many U.S. scientists are highly skeptical 
because it’s based on a concept that the National Institutes of Health shelved in 1994.”  FDA Allows Large-
Scale Test of AIDS Vaccine, THE COLUMBUS DISPATCH (Ohio), June 4, 1998, at 5A. 
18
  See Bill Hutchinson, Firm Gets OK to Test AIDS Drug, DAILY NEWS (New York), June 4, 1998, 
at 2.  
19
  See Peter Alford, Thais to Test HIV Vaccine, THE AUSTRALIAN, Feb. 11, 1999, at 7.  
20
  AIDSINFO Phase III, supra note 16.   
21
  Aphaluck Bhatiasevi, VaxGen to Stop Funding of Vaccine Trial, BANGKOK POST, July 2, 2003.  
22
  AIDSINFO Phase III, supra note 16.  
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participation. The population of 5,000 research subjects recruited in the 
United States was comprised of non-monogamous gay men or 
heterosexuals.23  Injection drug users were excluded from participating in the 
U.S. trials.24  Those who designed the study believed it would be too 
difficult to follow a population of injection drug users in the United States.25  
In contrast, the Thai version of the study was conducted exclusively among 
2,500 uninfected injection drug users attending 17 drug treatment clinics in 
Bangkok.26  In other words, while the use of injection drugs was grounds for 
exclusion from the U.S. trials, it was a requirement for participation in the 
Thai trials. 
For the purposes of this discussion, the results of the AIDSVAX 
vaccine trial are of little significance.  The trials conducted in both the 
United States and Thailand ultimately showed that neither form of the 
vaccine effectively prevented HIV infection among study participants.27  
However, the vaccine trials provide an important context for examining the 
legal and ethical issues raised by international research.  
As evidenced by the selection criteria, researchers generally follow 
populations that are considered to be at high risk of exposure due to sexual 
contact or injection drug use.  While health officials are obligated to ensure 
that all participants benefit from known prevention methods—such as the 
use of condoms and clean syringes—the studies will only be informative if 
                                           
23
  See Elizabeth Neus, U.S. Clears Test of AIDS Vaccine, CHICAGO SUN-TIMES, June 4, 1998, at 22.  
24
  CLINICALTRIALS.GOV, NATIONAL INSTITUTES OF HEALTH, Effectiveness of an HIV Vaccine in 
HIV-Negative Adults in North America Who Are at Risk of HIV Infection (2005), 
http://www.clinicaltrials.gov/ct/show/NCT00002441?order=1. 
25
  See CHRIS BEYRER, INTERNATIONAL AIDS VACCINE INITIATIVE, Injecting Drug Users and HIV 
Vaccine Trials: What Does the Science Say?, 6 IAVI REPORT 3, (2002), 
http://www.iavireport.org/Issues/0602/idus.asp; see also Thomas H. Maugh II, U.S.-Thai Trial for AIDS 
Vaccine Slated; Medicine: The Joint $36-million Effort Will Be the Largest Yet, LOS ANGELES TIMES, July 
9, 2002, at 6 (“Critics had argued that it would not be possible to complete the study because of the 
difficulties involved in monitoring large numbers of high-risk patients for three years or longer”). 
26
  See CLINICALTRIALS.GOV, NATIONAL INSTITUTES OF HEALTH, Effectiveness of AIDSVAX B/E 
Vaccine in Intravenous Drug Users in Bangkok, Thailand  (2005), 
http://www.clinicaltrials.gov/ct/show/NCT00006327?order=5; see also AIDSINFO Phase III, supra note 16 
(All injection drug users who participated in the trial were automatically enrolled in drug treatment and 
maintenance programs at the Thai clinics to help them stop using drugs and reduce their risk of HIV 
infection).  According to available estimates, there are anywhere from 100,000 to 250,000 injection drug 
users in Thailand.  HUMAN RIGHTS WATCH, Thailand, Not Enough Graves: The War on Drugs, HIV/AIDS, 
and Violations of Human Rights 2 (June 2004), available at 
http://www.hrw.org/reports/2004/thailand0704/thailand0704.pdf [hereinafter HUMAN RIGHTS WATCH].   
27
  See AIDS VACCINE CLEARINGHOUSE, AIDS Vaccine Advocacy Coalition, Frequently Asked 
Questions: When Will the Next Phase III Trial of an AIDS Vaccine Begin and When Will the Results be 
Known?, (2003), at http://www.aidsvaccineclearinghouse.org/cfaq5.htm; see also Jane E. Allen, After a 
Promising Vaccine Fails in Trials, Researchers Channel Efforts and Optimism Toward Other Possibilities, 
LOS ANGELES TIMES, Mar. 3, 2003, Part 6, at 3.  
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some of the participants are exposed to the HIV virus.28  A document from 
the U.S. Department of Health and Human Services notes that “[r]egardless 
of the best efforts at HIV prevention counseling, some individuals will 
continue to take risks.  By comparing the rates of infection among those at 
risk in both [experimental and control] groups, researchers will be able to 
determine if the vaccine helps protect these [exposed] individuals from 
infection.”29  Thus, while the investigators have an ethical obligation to 
inform participants about minimizing their exposure to HIV, they have a 
scientific interest in studying individuals who are exposed to the virus.  
B. Privately-Funded International Research Creates the Potential for 
Exploitation of Resource-Deprived Countries 
Clinical research has changed significantly in recent years due to 
increased commercialization of research, proliferation of multi-site trials 
around the globe, 30 and expansion of research into novel areas such as 
preventive HIV vaccines.  VaxGen’s decision to conduct the AIDSVAX 
clinical trials in the United States and Thailand reflects the growing trend in 
international biomedical research.31  In addition to the increasingly 
international scope of clinical research, the source of funding has shifted 
from the public sector to the private sector.32  Although there are many 
reasons for the expansion of private sector research into developing 
countries, scientific and financial advantages are probably the most 
important for pharmaceutical companies.33  Research subjects in developing 
countries are generally exposed to fewer drugs than patients in more 
industrialized countries.34  Conducting trials in developing countries allows 
pharmaceutical companies to bring their drugs to market faster (due to 
reduced research costs, access to greater numbers of subjects, and weaker 
regulations), and to develop new markets for approved drugs.35  In addition, 
                                           
28
  See GRADY, supra note 11, at 121 (“To run a scientifically useful study, the community must have 
a high incidence of HIV and of members at risk of acquiring HIV”). 
29
  Id. 
30
  See Mark R. Yessian, Reflections from the Office of the Inspector General, in INSTITUTIONAL 
REVIEW BOARD: MANAGEMENT AND FUNCTION 10 (Robert J. Amdur & Elizabeth A. Bankert eds., 2002). 
31
  See Alice K. Page, Ethical Issues in International Biomedical Research: An Overview, 37 J. 
Health L. 629, 633 (2004); see also Emanuel, supra note 3, at 289 (“Sponsorship of research is increasingly 
commercial, and studies are frequently conducted in sites outside the United States”). 
32
  See Page, supra note 31.  
33
  Id. 
34
  See RUTH MACKLIN, DOUBLE STANDARDS IN MEDICAL RESEARCH IN DEVELOPING COUNTRIES 7 
(2004).  
35
  See Page, supra note 31, at 632-33; see also MACKLIN, supra note 34, at 7.  
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financial and regulatory burdens create disincentives for conducting research 
in countries such as the United States.36 
The increasingly private nature of biomedical research raises legal and 
ethical concerns about the potential for exploitation37 of resource deprived 
countries.38  Developing countries may not have legal requirements in place 
for reviewing and conducting research, and may lack the financial resources 
to implement programs for legal and ethical review of research.39  Thailand 
has been referred to as both a developing nation and a “newly industrialized” 
nation, as a reflection of its status between the richest and poorest 
countries.40  Legislation is an important source of law in Thailand,41 but the 
legislature has not formally enacted regulatory protections for human 
subjects.42  In response to the increasing presence of HIV in Thailand, public 
health officials developed a series of “National Plans” to address the 
problem.43  The National Plans allow Thai officials to coordinate efforts 
among government agencies to find an effective vaccine and to slow the 
spread of the HIV epidemic.44 
However, the fact remains that Thailand lacks formal legislation on 
human experimentation.45  Successive governments have failed to introduce 
the legislation needed to protect trial subjects, rationalizing that more serious 
                                           
36
  In many cases, multi-center trials are not subject to a single formal oversight structure in the 
United States. See INSTITUTE OF MEDICINE, RESPONSIBLE RESEARCH: A SYSTEMS APPROACH TO 
PROTECTING RESEARCH PARTICIPANTS 35 (2003). 
37
  Ruth Macklin, a prominent bioethicist, asserts that “[e]xploitation occurs when wealthy or 
powerful individuals or agencies take advantage of the poverty, powerlessness, or dependency of others by 
using the latter to serve their own ends (those of the wealthy or powerful) without adequate compensating 
benefits for the less powerful or disadvantaged individuals or groups.”  MACKLIN, supra note 34, at 101-02.  
38
  See A.A. Hyder et al., Ethical Review of Health Research: A Perspective From Developing 
Country Researchers, 30 J. Med. Ethics 68 (2004).  
39
  See William Dubois, New Drug Research, the Extraterritorial Application of FDA Regulations, 
and the Need for International Cooperation, 36 VAND. J. TRANSNAT’L L. 161, 194-96 (2003); see also 
Page, supra note 31, at 633. 
40
   See MACKLIN, supra note 34, at 10.  
41
  LEGAL SYSTEMS OF THE WORLD: A POLITICAL, SOCIAL, AND CULTURAL ENCYCLOPEDIA, Vol. IV, 
at 1616 (Herbert M. Kritzer, ed., 2002).  Legislative power is vested in the National Assembly 
(Rathasapha), which is comprised of the Senate (Wuthisapha) and the House of Representatives (Sapha 
Phuthaen Ratsadon).  Id. 
42
  See A Poison Pill?, BANGKOK POST, Nov. 21, 2001.   
43
   After the National AIDS Prevention and Control Plan (1992-1996), Thailand’s National AIDS 
Prevention and Control Commission formulated the National Plan for Prevention and Alleviation of 
HIV/AIDS (1997-2001), and launched a third National Plan for 2002-2006.  See AIDSINFO Phase III, supra 
note 16; see also AVERT.ORG, HIV & AIDS in Thailand (2005), http://www.avert.org/aidsthai.htm.   
44
  See AIDSINFO Phase III, supra note 16; see also JOINT UNITED NATIONS PROGRAMME ON 
HIV/AIDS IN THAILAND, (Draft) 2004 Thailand Country Profile: HIV/AIDS Situation in Thailand and 
National Response to the Epidemic (2004), available at http://www.un.or.th/unaidsth/related_ 
document1.php (follow “2004 Thailand Country Profile” hyperlink). 
45
  See A Poison Pill?, supra note 42.   
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national problems must be given priority.46  Suntaree Vitayanatpaisan, 
assistant professor of Chulalongkorn’s Faculty of Pharmaceutical Sciences, 
remarked that “[w]e’ve pushed and pushed to try to finalise legislation to 
protect trial subjects …. Is the government trying to say that researchers are 
allowed to treat humans like guinea pigs?”47  Suntaree blames the 
government bureaucracy for sidelining legislation designed to protect human 
subjects in Thailand.48 
In the absence of formal legal protections for human subjects, several 
university-based ethics committees have been established to monitor 
biomedical research in Thailand.49  The VaxGen trial received an ethics 
review and approval from the Bangkok Metropolitan Administration, the 
Faculty of Tropical Medicine of Mahidol University, the Ethical and 
Scientific Review Committees of the Thailand Ministry of Public Health 
(“MOPH”),50 and the Thailand Food and Drug Administration.51  In addition, 
the Thai Safety and Monitoring Board evaluated the results of the trial after 
thirty months.52  While efforts to conduct ethical review in Thailand are 
commendable, Thailand lacks a formal regulatory body with the “teeth” to 
enforce such requirements.53  Although the Medical Council of Thailand 
encourages biomedical researchers to obtain informed consent from trial 
subjects, without formal legislation, the vulnerable public must rely on 
researchers’ voluntary compliance with ethical standards.54 
When research is proposed, authorities such as the Thai MOPH may 
not be in the optimal position to determine what is best for Thai research 
subjects.55  Local researchers stand to gain experience and prestige through 
international collaboration, and money flows from the researchers to 
                                           
46
  Draft legislation to protect human subjects was taken to the National Research Committee in 1975, 
and then rejected by the Office of the Permanent Secretary for University Affairs; in 1993 a final draft of 
the legislation was proposed to parliament, but no action was taken.  See id.   
47
  Id.   
48
  Id.   
49
  Id.   
50
  See Aphaluck Bhatiasevi, AIDS Vaccine Approved by Ethics Panel: Drug Injectors to Take Part in 
Trial, BANGKOK POST, Nov. 26, 1997, at 4.  
51
  See AIDSINFO Phase III, supra note 16. 
52
  See AIDS/Vaccine Trial: Recruitment of Volunteers 40% Short: Researchers Hopeful of Reaching 
Target, BANGKOK POST, Mar. 23, 2000.  
53
  The Forum for Ethical Review Committee in Thailand (“FERCIT”) works solely on a voluntary 
basis; the Medical Council of Thailand steps in only when a subject files a complaint, and does not take a 
proactive role.  See A Poison Pill?, supra note 42.   
54
  Id. (“Many researchers don’t look for approval from FERCIT or anywhere”). 
55
  See MACKLIN, supra note 34, at 23.  
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research institutions,56 possibly even to the government itself.57  In addition, 
“biomedical research in Thailand could strengthen the nation’s bargaining 
power with pharmaceutical companies,” when it comes to obtaining 
essential drugs.58 
Thai activists note that without legislation to protect research 
participants, volunteers and communities are open to being exploited by 
pharmaceutical manufacturers.59  Professor Thada Seublinwong of 
Chulalongkorn University encourages researchers to be “sensitive to 
community issues as well as individual rights.”60  Professor Seublinwong 
offered the example of researchers using Thai medical facilities and research 
subjects, and then pulling out all of the resources after the study, which he 
says would be “unacceptable and unethical.”61  In fact, the economic motive 
for the AIDSVAX research was highlighted when VaxGen considered 
prematurely halting the Thai trials on commercial grounds.62  Clinical trials 
are expensive, and when it became clear that the AIDSVAX vaccine was not 
effective, VaxGen considered pulling out of Thailand before the final 
analysis of the data was complete.63  Mahidol University epidemiologist 
Dwip Kitayaporn noted that VaxGen’s threat of withdrawal from the trial 
“should teach Thailand and other developing countries to be more careful 
and not fall into the trap of private business.”64 
In contrast to the substantial number of financial interests served by 
clinical research, the Thai MOPH also has a duty to protect the small 
population of potential research subjects.  Wealthy and powerful sponsors 
such as VaxGen may influence institutions such as the Thai MOPH to 
approve clinical trials at the expense of the research population.65  In their 
eagerness for an HIV vaccine and research funding, the public health 
officials and scientists of Thailand failed to protect a small, vulnerable 
segment of society:  the injection drug users who participated in the 
research.  As evidenced by the unscientific desire of VaxGen to halt the 
                                           
56
   According to the Drug Issue Research Group, a voluntary group of medical people and activists in 
Thailand, enormous sums are spent on medical research projects in Thailand every year; a single project 
can cost up to $500 million.  See A Poison Pill?, supra note 42.   
57
   See MACKLIN, supra note 34, at 23.  
58
   A Poison Pill?, supra note 42.    
59
   See id. 
60
   Id. 
61
   Id.   
62
   See VaxGen Set to Pull Plug on AIDS Vaccine Trial, THE NATION (Thailand), July 2, 2003 (“If 
they leave and allowed all Thai efforts to count for nothing, it could wreck the chances of future clinical 
trials in developing countries”).  
63
  See id.  
64
  Aphaluck Bhatiasevi, Ministry Says Vaccine Trial Will Go Ahead, BANGKOK POST, July 3, 2003.  
65
   See MACKLIN, supra note 34, at 23-24; see also A Poison Pill?, supra note 42.    
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clinical trial before its completion, the power of profit motive necessitates 
strong ethical and legal protections.  While Thailand has yet to see court 
battles over human clinical trials, circumstances will likely change if the 
government fails to take decisive legislative action in the near future.66   
III. FEDERAL REGULATIONS AND ETHICAL PRINCIPLES ABSENT IN 
THAILAND PROTECT HUMAN SUBJECTS IN THE UNITED STATES 
In recent history, a number of protections have evolved to minimize 
the harm to research participants. The risk of harm to participants arises 
because unlike treating physicians, who aim to improve the health of the 
individual, biomedical researchers seek to advance generalized knowledge 
that will benefit broader populations, often at the expense of the individual.67  
In other words, the researcher “must often subordinate an enrollee’s personal 
interests and desires to the protocol.”68  The creation of international 
guidance documents and domestic laws marked the recognition of the need 
to protect individual rights over the interest of the researcher in the scientific 
endeavor.69  The principles from international guidance documents are 
important because they are often used as a definitive source of authority by 
non-governmental organizations, investigators, and both national and local 
committees that review the ethical dimensions of research.70 
A. Historical Foundations for the Protection of Human Subjects   
Historically, informed consent has functioned as one of the primary 
protections for human subjects of biomedical research.  Informed consent 
provides a process for ensuring and documenting that a research participant 
(or his or her legally authorized representative) has acted according to his or 
her informed, considered, and freely made judgment.71  Following World 
War II and Nazi medical experimentation, the Nuremberg Code declared in 
1947 that “[t]he voluntary consent of the human subject is absolutely 
                                           
66
   See A Poison Pill?, supra note 42.   
67
  See E. Haavi Morriem, Litigation in Clinical Research: Malpractice Doctrines Versus Research 
Realities, 32 J. L. MED. & ETH. 474, 475 (2004). 
68
  Id. 
69
  See Joanne Roman, U.S. Medical Research in the Developing World: Ignoring Nuremberg, 11 
CORNELL J.L. & PUB. POL’Y 441, 448 (2002). 
70
  See MACKLIN, supra note 34, at 19.  
71
  See generally Belmont Report, supra note 4, at 23,195 (discussing the application of informed 
consent principles, including the provisions for sufficient information, adequate comprehension, and 
voluntariness); see also INSTITUTE OF MEDICINE, supra note 36, at 95 (noting that obtaining written 
“informed consent” is tangential to the process of informed consent). 
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essential.”72  The Nuremberg Code not only requires the consent of research 
subjects, but also maintains that the consent must be voluntary (free from 
coercion), competent, and informed.73    
For many years after the creation of the Nuremberg Code, most 
physicians believed that the Code primarily applied to war crimes, and not to 
the medical establishment.74  Subsequent documents developed by 
international organizations provided guidelines for ethics in research, and 
were intended to apply to multinational and intranational research.  For 
example, the Declaration of Helsinki was developed and adopted by the 
World Medical Assembly in 1964.75  In addition to requiring informed 
consent, the Declaration of Helsinki calls for additional protections for 
vulnerable and incompetent subjects.76  The Declaration of Helsinki also 
espouses the use of ethical review committees, which are empowered to 
evaluate “information regarding funding, sponsors, institutional affiliations, 
other potential conflicts of interest and incentives for subjects,” and have the 
right to monitor ongoing trials.77   
In addition, the World Health Organization (“WHO”) and the Council 
for International Organizations of Medical Sciences (“CIOMS”) issued a 
new set of guidelines designed to aid in the application of the Declaration of 
Helsinki IV.78  The 1993 version of the CIOMS guidelines specifically 
addresses developing countries hosting clinical trials.79  In addition to 
informed consent, the CIOMS guidelines also require that research protocols 
are prospectively reviewed by independent ethical review bodies.80 
Guideline 3 specifies that an external sponsoring organization (such as 
                                           
72
  See The Nuremberg Code (1947), reprinted in SOURCE BOOK IN BIOETHICS 11-12 (Albert R. 
Jonsen et al. eds., 1998) [hereinafter Nuremberg Code].  
73
  See GEORGE J. ANNAS ET AL., INFORMED CONSENT TO HUMAN EXPERIMENTATION 7 (1977).    
74
  See Roman, supra note 69, at 451 (noting that the “[b]ecause judges created the Code, and not 
other researchers, physician-researchers thought the Code inapplicable to their own practices”). 
75
  See WORLD MEDICAL ASSOCIATION, World Medical Association Declaration of Helsinki: Ethical 
Principles for Medical Research Involving Human Subjects (1964), 
http://www.wma.net/e/policy/pdf/17c.pdf (amended in 2000 and clarified in 2002 and 2004) [hereinafter 
Declaration of Helsinki]; see also Roman, supra note 69, at 451-52. 
76
  See Declaration of Helsinki, supra note 75, at paras. 22-24.  
77
  Id. at para. 13.  
78
  See COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES (“CIOMS”) in 
collaboration with the WORLD HEALTH ORGANIZATION (“WHO”), International Ethical Guidelines for 
Biomedical Research Involving Human Subjects (2002), http://www.cioms.ch/frame_guidelines_ 
nov_2002.htm [hereinafter CIOMS Guidelines]; see also LAWRENCE O. GOSTIN & ZITA LAZZARINI, 
HUMAN RIGHTS AND PUBLIC HEALTH IN THE AIDS PANDEMIC 128 (1997). 
79
  The CIOMS Guidelines require investigators to obtain voluntary informed consent from every 
prospective subject, but they also recognize that it may be challenging to obtain informed consent from 
subjects in countries with low levels of education.  See CIOMS Guidelines, supra note 78, at Guideline 4. 
80
  See CIOMS Guidelines, supra note 78, at Guideline 2.  
112                                      PACIFIC RIM LAW & POLICY JOURNAL VOL. 15 NO. 1 
VaxGen) should submit the research protocol for ethical and scientific 
review “in the country of the sponsoring organization, and the ethical 
standards applied should be no less stringent than they would be for research 
carried out in that country.”81 
The Joint United Nations Programme on HIV/AIDS (“UNAIDS”) has 
also issued a guidance document titled “Ethical Considerations in HIV 
Preventive Vaccine Research,” which directly relates to the VaxGen clinical 
trials in Thailand.82  The UNAIDS document highlights some of the special 
issues that ethical review committees should consider when reviewing 
international research.  First, HIV preventive vaccine trials should only be 
carried out in countries and communities that have the capacity to conduct 
appropriate independent and competent scientific and ethical review.83  
Additionally, the research protocol should describe the social contexts of a 
proposed research population, so that reviewing bodies can evaluate whether 
there may be exploitive conditions or increased vulnerability among 
potential research participants.84  Like other guidance documents, UNAIDS 
requires informed consent, as well as a plan for monitoring the continuing 
adequacy of consent among research subjects.85  In addition, UNAIDS 
specifically calls for special measures to protect persons, including 
intravenous drug users, who may be limited in their ability to give informed 
consent due to their social or legal status.86 
While the aforementioned documents declare the importance of 
informed consent and suggest the utility of prior independent ethical review 
to protect human subjects, none create legally enforceable obligations for 
states or individuals.87  Nonetheless, the Nuremberg Code and Declaration of 
Helsinki,88 and to a lesser extent, the CIOMS and UNAIDS guidelines, have 
all influenced the creation of law and policy in the United States.  
Accordingly, U.S. regulations incorporate the legal and ethical requirements 
of informed consent and prior ethical review.   
                                           
81
  Id. at Guideline 3. 
82
  See JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS (UNAIDS), UNAIDS Guidance 
Document, Ethical Considerations in HIV Preventive Vaccine Research (2000), http://www.unaids 
.org/html/pub/publications/irc-pub01/jc072-ethicalcons_en_pdf.pdf [hereinafter UNAIDS Guidance]. 
83
  Id. at 21. 
84
  Id. at 22. 
85
  Id. at 32, 39.  
86
  Id. at 36-37.  
87
  See Benjamin Mason Meier, International Protection of Persons Undergoing Medical 
Experimentation: Protecting the Right of Informed Consent, 20 BERKELEY J. INT’L L. 513, 531 (2002); see 
also Finnuala Kelleher, The Pharmaceutical Industry’s Responsibility for Protecting Human Subjects of 
Clinical Trials in Developing Nations, 38 COLUM. J. L. & SOC. PROBS. 67, 80-81 (2004).  
88
  The U.S. federal regulations of human subjects research specifically reference both the Nuremberg 
Code and the Declaration of Helsinki.  See Chang, supra note 2, at 346. 
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B. The Belmont Report Provides the Ethical Foundations for the 
Protection of Human Subjects in the United States 
In the United States, the National Commission for the Protection of 
Human Subjects of Biomedical and Behavioral Research created the 
Belmont Report to provide an “analytical framework” for the resolution of 
“ethical problems arising from research involving human subjects.”89  The 
Belmont Report identified three ethical principles that govern research on 
human subjects:  (1) respect for persons (autonomy), (2) beneficence, and 
(3) justice. 90   
The principle of respect for persons is comprised of two moral 
requirements: (1) that individuals should be treated as autonomous agents, 
and (2) that persons with diminished autonomy are entitled to protection.91  
The Belmont Report clarifies those requirements, explaining that for most 
research on human subjects “respect for persons demands that subjects enter 
into the research voluntarily and with adequate information.”92  In other 
words, the principle of respect for persons requires the provision of informed 
consent.  Informed consent is assessed according to the adequacy of the 
information, comprehension by the subject, and voluntariness (consent free 
of coercion and undue influence).93 
According to the Belmont Report, the principle of “beneficence” can 
be expressed by two general rules: “(1) do not harm, and (2) maximize 
possible benefits and minimize possible harms.”94  While a research subject 
can balance the risks and benefits of participation individually, ethical 
review committees must also weigh these factors on behalf of the study 
population.  
The principle of “justice” requires a fair distribution of the risks and 
benefits in the selection of research subjects.95  Justice is a particularly 
important factor to consider in the context of international research, because 
it implies that certain nations and populations must not disproportionately 
bear the burdens of biomedical research.96  Justice concerns have often 
focused on the exploitation of subjects in developing countries with regard 
                                           
89
  See Belmont Report, supra note 4, at 23,193. 
90
  Id. at 23,193-94. 
91
  Id. at 23,193. 
92
  Id. at 23,194.  
93
  Id. at 23,195. 
94
   Id. at 23,194.  
95
  Id. 
96
  See id. at 23,196 (“Individual justice in the selection of subjects would require that researchers 
exhibit fairness: thus, they should not offer potentially beneficial research only to some patients who are in 
their favor or select only ‘undesirable’ persons for risky research”). 
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to subject recruitment.97  The Belmont Report cautions that vulnerable 
populations should be “protected against the danger of being involved in 
research solely for administrative convenience, or because they are easy to 
manipulate as a result of their illness or socioeconomic condition.”98  Justice 
demands that the risks and benefits of research are spread evenly across the 
globe, and that cost-benefit ratios do not vary with geographic location.99  
By promoting the concepts of respect for persons, beneficence, and justice, 
the Belmont Report provides the ethical foundation for the current federal 
laws governing research on human subjects in the United States. 
C. The Statutory Basis for Protecting Human Subjects Derives from the 
Common Rule and FDA Regulations  
Federal regulations implement the ethical principles of the Belmont 
Report,100 but the regulations only control certain types of research on 
human subjects.   Two separate sections of the Code of Federal Regulations 
may apply to clinical trials on human subjects, depending on the funding 
source.  
The Common Rule was created in 1991 when the President’s 
Commission recommended that all federal agencies adopt U.S. Department 
of Health and Human Services (“DHHS”) regulation 45 CFR part 46, 
governing research on human subjects.101  Subpart A of the regulations was 
thereafter endorsed by seventeen federal agencies and departments that fund 
research on human subjects,102 creating a unified system of protections.  If a 
clinical trial involving human subjects is conducted by the federal 
government, supported by federal grants, or otherwise subject to regulation 
by a federal department or agency, the Common Rule applies.103 
Under certain circumstances, compliance with the Common Rule may 
not be legally required of a clinical trial involving human subjects.104  For 
                                           
97
  See MACKLIN, supra note 34, at 68.   
98
   See Belmont Report, supra note 4, at 23,197. 
99
  See Ruth Macklin, Justice in International Research, in BEYOND CONSENT: SEEKING JUSTICE IN 
RESEARCH 132 (Jeffrey P. Kahn et al. eds., 1998). 
100
  See Berman, supra note 10, at 308. 
101
  See GRADY, supra note 12, at 44-45 (The DHHS regulations were originally codified in 1981 at 45 
C.F.R. § 46, and were most recently revised in 1991); see also Sharona Hoffman, Regulating Clinical 
Research: Informed Consent, Privacy, and IRBs, 31 CAP. U. L. REV. 71, 75 (2003). 
102
  See INSTITUTE OF MEDICINE, supra note 36, at 138; see also Emanuel, supra note 3, at 282. 
103
  45 C.F.R. §§ 46.101(a), 46.102(e) (2005).  U.S. federal policy requires that each institution 
engaged in federally sponsored human subject research file an “assurance” of compliance with the Office 
of Human Research Protections (“OHRP”).  See Laura A. McNay et al., Regulatory Approvals in a Large 
Multinational Clinical Trial: the ESPRIT Experience, 23 CONTROLLED CLINICAL TRIALS 59, 60-61 (2002).  
104
  See Emanuel, supra note 3, at 283.  
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example, research that is entirely funded by private sources (rather than 
government sources) lacks the requisite federal nexus for the Common Rule 
to apply.105  In the case of privately-funded research by pharmaceutical 
companies, the federal government would need an additional basis for 
regulating.  
The FDA did not sign on to the Common Rule, and therefore has a 
separate basis for regulating research on human subjects.106  The FDA 
applies requirements similar to the Common Rule to clinical research 
conducted as a part of the approval process for drugs, devices, or biologics 
(which include vaccines).107  When a sponsor of a drug or vaccine seeks to 
study the product to learn if it is suitable for marketing, the sponsor must file 
an investigational new drug application (“IND”) with the FDA.108  If IND 
approval is secured by an investigator, then the study may begin, subject to 
strict compliance with the protocols accepted by the FDA.109  Even if a 
private pharmaceutical company conducts research on populations outside of 
the United States,110 the research will be subject to FDA requirements if the 
company ultimately intends to seek FDA approval for use of the product in 
the United States.111  FDA regulations unquestionably have full legal effect 
in the United States, and compliance is mandatory.112   
In sum, the federal system of protections applies only to research 
funded by a federal agency that is subject to the Common Rule, and to 
private entities that will ultimately seek FDA review and approval.113 
                                           
105
  45 C.F.R. § 46.101(a).  
106
   See Emanuel, supra note 3, at 282 (discussing 21 C.F.R. §§ 50, 56 (2005)); see also Chang, supra 
note 2, at 341-42. 
107
  See Emanuel, supra note 3, at 282. 
108
  See Dale E. Hammerschmidt, Understanding the FDA’s IND Process, in INSTITUTIONAL REVIEW 
BOARD: MANAGEMENT AND FUNCTION 323 (Robert J. Amdur & Elizabeth A. Bankert eds., 2002). The 
overarching purposes of the IND process are to “ensure the rights and welfare of study subjects and to 
ensure the quality and integrity of the data on which licensing applications are based.” Id. at 325.  
109
  Id. at 325. 
110
  45 C.F.R. § 46.101(a); 21 C.F.R. § 50.1(a).  
111
  45 C.F.R. § 46.102(e).  
112
  FDA’s Center for Biologics Evaluation and Research (“CBER”) is responsible for regulating 
vaccines in the United States.   See David G. Forster & Gary L. Chadwick, International Conference on 
Harmonisation, in INSTITUTIONAL REVIEW BOARD: MANAGEMENT AND FUNCTION 316 (Robert J. Amdur & 
Elizabeth A. Bankert eds., 2002); see also U.S. Food and Drug Administration, Center for Biologics 
Evaluation and Research, Vaccine Product Approval Process, July 27, 2002, available at 
http://www.fda.gov/cber/vaccine/vacappr.htm (current authority for the regulation of vaccines resides 
primarily in Section 351 of the Public Health Service Act and specific sections of the Federal Food, Drug 
and Cosmetic Act). 
113
  See INSTITUTE OF MEDICINE, supra note 36, at 138. 
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D. The Federal Regulations Create Safeguards for Research Subjects 
The Common Rule and the FDA regulations, as well as the 
aforementioned international declarations and guidelines, require two 
primary protections for research subjects: individual voluntary informed 
consent, and prior review of proposed research by an independent ethical 
review committee.114  Ethical evaluation of clinical trials using the Belmont 
Report framework is often required to ensure that the regulations are 
appropriately implemented.  
1. Individual Voluntary Informed Consent Promotes Autonomy and 
Beneficence 
The general requirements for informed consent are virtually identical 
in the Common Rule and the FDA regulations.115  Subjects (or their legally 
authorized representatives) must give “legally effective informed consent” in 
order to participate in research.116  To clarify the information that must be 
provided to a research subject (or their legally authorized representative), the 
regulations list eight basic elements:  
(1) a statement that the study involves research, as well as a 
description of the research and its purposes; (2) a description of 
reasonably foreseeable risks; (3) a description of reasonably 
expected benefits; (4) disclosure of appropriate alternatives; (5) 
a statement about maintenance of confidentiality; (6) for 
research involving more than minimal risks, an explanation 
about possible compensation if injury occurs; (7) information 
about how the subject can have pertinent questions answered; 
and (8) a statement that participation is voluntary (i.e., refusal 
to participate involves no penalties or loss of benefits).117 
It is important for investigators to understand the difference between 
“the presentation of the information, and even the signing of the consent 
document, and bona fide consent.”118  A document with a signature is not 
consent, but is merely a record of what was supposed to have been 
                                           
114
  Emanuel, supra note 3, at 282. 
115
  See 45 C.F.R. 46 § 116 (2005); 21 C.F.R. § 50.20 (2005); see also Bonnie M. Lee, U.S. FOOD AND 
DRUG ADMINISTRATION, Comparison of FDA and HHS Human Subject Protection Regulations, 2000, 
available at http://www.fda.gov/oc/gcp/comparison.html.  
116
  See 45 C.F.R. § 46.116 (2005).  
117
  Id. at § 46.116; 21 C.F.R. § 50.25 (2005).  
118
  Robin L. Penslar, The IRB’s Role in Editing the Consent Document, in INSTITUTIONAL REVIEW 
BOARD: MANAGEMENT AND FUNCTION 233 (Robert J. Amdur & Elizabeth A. Bankert eds., 2002). 
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communicated between researchers and prospective participants.119  
According to the Belmont Report, informed consent is evaluated by the 
adequacy of the information provided, the subject’s comprehension of the 
information, and the voluntariness of the consent.120 
2. Prior Independent Ethical Review Strengthens Informed Consent and 
Promotes Beneficence and Justice 
Institutional Review Boards (“IRBs”) are responsible for reviewing 
the ethical facets of proposed human research.  When research is not subject 
to federal regulation, investigators “are under no formal obligation to 
monitor the ethical aspects of research,” but may voluntarily elect to do 
so.121  In contrast, all clinical trials under federal jurisdiction must be 
examined and approved by a U.S. IRB prior to commencement.122  IRBs are 
required by the federal regulations to ensure that: (1) informed consent is 
obtained from subjects and documented (respect for persons, or 
autonomy),123  (2) the risks to subjects are minimized and are reasonable in 
relation to benefits (beneficence),124 and (3) the selection of subjects is 
equitable (justice).125 
Privately-funded researchers that are not required to comply with the 
Common Rule must comply with FDA regulations126 when research involves 
the investigational use of biologics such as vaccines, and the institution 
plans to market the biologic in the United States, regardless of the source of 
funding.127  However, if an institution conducts research that is subject to 
both the Common Rule and the FDA regulations, the IRB review must 
comply with both sets of regulations.128  Requiring researchers and review 
                                           
119
  See INSTITUTE OF MEDICINE, supra note 36, at 95; see also Office for the Protection From 
Research Risks (now Office for Human Research Protections), U.S. Department of Health and Human 
Services, Tips on Informed Consent (1993), http://www.hhs.gov/ohrp/humansubjects/guidance/ictips.htm. 
120
  See Belmont Report, supra note 4, at 23,195. 
121
  Robert J. Amdur & Elizabeth A. Bankert, The IRB: Definition and Federal Oversight, in 
INSTITUTIONAL REVIEW BOARD: MANAGEMENT AND FUNCTION 27 (Robert J. Amdur & Elizabeth A. 
Bankert eds., 2002). 
122
  In the U.S., research on human subjects must be approved by the appropriate IRB. 45 C.F.R. § 
46.101(a)(2) (2005); see generally Barbara A. Noah, Bioethical Malpractice: Risk and Responsibility in 
Human Research, 7 J. HEALTH CARE L. & POL’Y 175, 181-206 (2004); Hoffman, supra note 101, at 76; 
Berman, supra note 10, at 309; Chang, supra note 88, at 342.  
123
  45 C.F.R. § 46.111(a)(4), 46.111(a)(5) (2005); 21 C.F.R. §§ 56.111(a)(4), 56.111(a)(5) (2005).  
124
  45 C.F.R. §§ 46.111(a)(1), 46.111(a)(2) (2005); 21 C.F.R. §§ 56.111(a)(1), 56.111(a)(2) (2005).  
125
  45 C.F.R. § 46.111(a)(3) (2005); 21 C.F.R. § 56.111(a)(3) (2005).  
126
  21 C.F.R. §§ 56.103 (2005).  
127
  See Robert J. Amdur, Differences Between DHHS and FDA Regulations, in INSTITUTIONAL 
REVIEW BOARD: MANAGEMENT AND FUNCTION 329 (Robert J. Amdur & Elizabeth A. Bankert eds., 2002). 
128
  Id. 
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committees to implement informed consent and ethical principles helps to 
ensure the equitable selection of subjects from diverse populations.129 
D. United States Regulations Apply to U.S.-Based Research Conducted in 
 Thailand 
Informed consent and IRB review protect the rights and welfare of 
research subjects in the United States by promoting autonomy, beneficence, 
and justice.  The strength of the protections must not be compromised when 
U.S. pharmaceutical companies conduct research abroad, particularly where 
clinical trials are conducted in vulnerable populations.130  In addition to Thai 
protections, United States federal regulations represent another layer of 
protection for research subjects.   
In the case of the AIDSVAX clinical trials, determining whether the 
Common Rule applies to research conducted outside U.S. borders is not a 
straightforward task.  If international research is funded through the 
Department of Health and Human Services (“DHHS”), then the Common 
Rule unquestionably applies.  However, the AIDSVAX trial was funded by 
VaxGen, a private pharmaceutical company that developed the AIDSVAX 
vaccine.  Despite the private nature of the funding, collaboration between the 
U.S. federal government and researchers in Thailand created a sufficient 
federal nexus to bring the research within the reach of the Common Rule.  
The National Institutes of Health (“NIH”) issued guidelines to help 
investigators determine whether collaborative research between intramural 
investigators and others in the United States and abroad is covered by 
federal requirements.131  According to the NIH, collaborative activities may 
include “substantive intellectual contributions to research techniques, 
protocol design, or interpretation of data.”132  If VaxGen collaborated with an 
entity supported by the NIH or another DHHS entity, then the research 
would be subject to the Common Rule.  The NIH declined to provide direct 
funding for the AIDSVAX trials, but the Centers for Disease Control and 
Prevention (“CDC”) collaborated with both United States and Thai 
institutions by providing epidemiologic and laboratory technical 
                                           
129
  See 45 C.F.R. §§ 46.111(a)(3), 46.111(a)(4). 
130
  See CIOMS Guidelines, supra note 78, at Guideline 13. 
131
  See NATIONAL INSTITUTES OF HEALTH, Guidelines for the Conduct of Research Involving Human 
Subjects at the National Institutes of Health, 12 (2004), available at http://ohsr.od.nih.gov/guidelines/ 
GrayBooklet82404.pdf.  
132
  Id.  
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assistance.133  The CDC assisted researchers in Thailand with statistical 
analysis (interpreted results, determined whether the vaccine was effective), 
consulted on implementation strategies and access, and conducted studies on 
the subject population.134 The CDC arguably “collaborated” with VaxGen 
when it provided “substantive intellectual contributions,” thus bringing the 
AIDSVAX research within the purview of the Common Rule.135 
Additionally, the United States exercises control over the introduction 
of new pharmaceutical products into the U.S. marketplace through the FDA, 
which requires informed consent136 and IRB review137 for research on 
human subjects.  Institutions that are not required to follow the Common 
Rule must comply with the FDA regulations when research involves the 
investigational use of biologics (such as vaccines), regardless of the source 
of research funding.138  Since the VaxGen vaccine products would ultimately 
require FDA approval, the research is subject to federal regulation by virtue 
of the FDA statute.139 
IV. UNITED STATES PROTECTIONS FOR HUMAN SUBJECTS WERE 
IMPROPERLY APPLIED TO THE THAI VACCINE TRIALS 
United States research regulations and practices cannot be directly 
applied in Thailand, where many cultural, social, and political factors 
operate to undermine the effectiveness of the protections.  In assessing 
whether the legal requirements for informed consent and IRB review are 
met, research should be measured against the underlying ethical principles 
that gave rise to the U.S. laws.140  The ethical substance of the U.S. 
regulations must be maintained in Thailand, even amid vastly different 
circumstances, because different contexts do not allow for the use of a lower 
ethical standard in assessing legal compliance.141  Researchers and review 
                                           
133
  See UNAIDS VACCINE ADVISORY COMMITTEE, Report from the Meeting of the UNAIDS Vaccine 
Advisory Committee, Geneva, 10 (1999), available at http://www.who.int/vaccine_research/diseases/ 
hiv/policy/en/report_june_99.pdf; see also AIDSINFO Phase III, supra note 16. 
134
  See CENTERS FOR DISEASE CONTROL AND PREVENTION, NCHSTP Program Briefing 2001: HIV 
Vaccine Research (2001), http://www.cdc.gov/nchstp/od/program_brief_2001/HIV%20Vaccine%20 
Research.htm.   
135
  See NATIONAL INSTITUTES OF HEALTH, supra note 131. 
136
  21 C.F.R. § 50.20. 
137
  21 C.F.R. § 56.103. 
138
  See Amdur, supra note 127, at 329. 
139
  Id.; 21 C.F.R. § 56.103. 
140
  See Gerald S. Schatz, Are the Rationale and Regulatory System for Protecting Human Subjects of 
Biomedical and Behavioral Research Obsolete and Unworkable, or Ethically Important but Inconvenient 
and Inadequately Enforced?, 20 J. CONTEMP. HEALTH L. & POL’Y 1, 31 (2003). 
141
 See Page, supra note 31, at 641-42.   
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boards must account for the factors in Thai culture that create special harms 
and vulnerabilities for the research population.  
A. Informed Consent in Thailand was Inadequate  
According to the Belmont Report framework, scientific research on 
human subjects must adhere to three ethical requirements for informed 
consent: adequate information, comprehension by the subject, and 
voluntariness, or the absence of coercion.142  The informed consent 
provisions of the Common Rule and the FDA regulations incorporate these 
ethical components.143  As a developing nation, Thailand presents 
researchers with “unique challenges” during the process of obtaining 
informed consent.144  In addition to concepts about research and individual 
choice that might be unfamiliar, participants “may be plagued by poverty, 
illiteracy, and limited access to health care services that make it difficult for 
them to give valid informed consent.”145  In the case of the AIDSVAX 
vaccine trials, conditions in Thailand, as well as the decision to study a 
population of injection drug users, created challenges for the informed 
consent process that did not exist in the United States.   
1. The Information Provided to Research Subjects was Inappropriate or 
Inaccurate for the Thai Population of Injection Drug Users 
Researchers in Thailand need to provide meaningful information 
through culturally appropriate channels, because the information necessary 
for informed consent involves complex concepts. 146  Researchers should 
present information that is appropriate for “research subjects from different 
backgrounds and with varying levels of education” to allow for a clear 
understanding of the nature and purpose of the research, and to promote “an 
informed and considered decision” about participation.147   
In vaccine clinical trials, complex scientific concepts such as 
“placebo” and “randomization” must be explained to potential volunteers.  
In a placebo-controlled design, some of the participants receive the vaccine 
                                           
142
  See Belmont Report, supra note 4, at 23,195. 
143
  See generally 45 C.F.R. § 46 (2005) and 21 C.F.R. § 56 (2005). 
144
  See Page, supra note 31, at 648.  
145
  Christine Pace et al., The Quality of Informed Consent in a Clinical Research Study in Thailand, 
27 IRB: ETHICS & HUMAN RESEARCH 9 (2003). 
146
  See Baruch A. Brody, Making Informed Consent Meaningful, 23 IRB: ETHICS & HUMAN 
RESEARCH 1, 3 (2001) (“Of particular importance is the development of useful general language that 
promotes an understanding of the general features of clinical trials”).   
147
  Page, supra note 31, at 648. 
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being tested, known as the “experimental group,” and the others receive no 
vaccine, known as the “placebo group.”148  The determination of which 
subjects get the vaccine and which do not is made by a process of 
“randomization.”  For example, of the 2,500 Thai volunteers, half were 
randomly given the AIDSVAX vaccine and the other half received placebo 
injections that did not include the vaccine.149   
When conceptually challenging issues such as placebos and 
randomization must be explained in order for participants to understand the 
research, particular care should be taken to ensure that explanations are clear 
and translations are appropriate.  In one clinical trial, when the U.S. and Thai 
consent forms were compared, it was determined that the Thai form was less 
clear in its definition of a “placebo.” 150  When this difference was brought to 
the attention of the Thai Ministry of Public Health, rather than clarifying the 
term, the Director defended the translation as being “appropriate and clear 
and understandable in its description of the concept of an inactive 
comparison pill, or placebo.”151  A later study of Thai research participants 
reinforced the idea that “randomization” was a problematic concept for 
participants to understand.152   
Another concept that should be clarified when obtaining informed 
consent from Thai research participants is the distinction between medical 
treatment and experimental research.  Several cultural reasons make truly 
informed consent difficult to achieve in Thailand at the present time, 
including the “relative lack of understanding of the nature of medical 
research in the lay population.”153  The doctor-patient relationship involves 
treatment for the benefit of the individual, while the researcher-subject 
relationship is not undertaken for the benefit of the individual participant.154  
Whereas the individual subject is primarily concerned with improving their 
health, the researcher seeks generally applicable scientific knowledge, which 
does not necessarily provide any benefit to the subject’s health.155  
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In addition to providing the appropriate information, the method by 
which the information is conveyed is also important for informed consent.  
The traditional one-on-one informed consent process commonly used in 
Western cultures may not be the best practice in Thailand.156  Researchers 
have noted that “[i]n all fields of medicine, not just HIV/AIDS, Thai 
subjects tend to be dominated by the health professional in the doctor-patient 
relationship.”157  For cultural reasons, open group interaction may be more 
appropriate in Thailand, where potential research participants are allowed to 
share experiences with peers when making decisions.158 
2. Researchers Did Not Adequately Address Barriers to the 
Comprehension of Injection Drug Users 
For informed consent to be truly valid, Thai research subjects must 
actually comprehend the information they are given.  However, a number of 
barriers to effective comprehension exist in the Thai study population, 
including illiteracy, injection drug use, misconceptions about the nature of 
research, and confusing recruitment practices.  A 1999 study of the 
comprehension and motives of volunteers for participating in medical 
research in Thailand159 noted that literacy may be a barrier to comprehension 
for some, particularly for those who lacked a secondary education.160  When 
most research participants come from lower-educated segments of the Thai 
population, the use of technical language in informed consent documents 
may be inappropriate for the intended audience.161  The previously discussed 
problems in translating research concepts (such as “placebo”) from English 
to Thai may exacerbate comprehension problems in subjects with literacy 
difficulties. 
In addition to general concerns about comprehension among Thai 
research participants, special issues arise due to the characteristics of the 
research population.  The group of subjects recruited for the clinical trials in 
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Thailand was entirely comprised of injection drug users.162  Addicts may not 
be able to give informed consent to treatment,163 even assuming that they are 
not under the influence of drugs at the time of recruitment.164  It is clear that 
acutely intoxicated people are impaired in their decisionmaking, but it is 
“less obvious to what extent these individuals are still decisionally impaired 
when they are not intoxicated.”165  When research subjects are selected from 
a group of injection drug users, it raises questions about the ability of the 
subjects to comprehend the research to which they are consenting. 
Volunteers should not be categorically excluded from clinical trials for 
merely belonging to the general class of injection drug users.  However, 
researchers must consider whether an actual impairment of decisional 
capacities would make voluntary research participation problematic for such 
individuals.166  A report by the National Bioethics Advisory Committee 
(“NBAC”) proposed that “subjects failing to exhibit a minimal degree of 
concern for [their] welfare should be deemed incapable of independent 
decision making.”167  Although the Thai study participants were enrolled in 
drug treatment programs, it is unlikely that all participants had successfully 
abandoned their addictions at the time of the trial.  Former and recovering 
addicts may be able to give informed consent to research if certain criteria 
have been met, such as being free from intoxication or withdrawal, as well 
as not having an intense “craving” at the time informed consent is 
obtained.168  In short, the presence of drug addiction at the time of 
enrollment should trigger a special inquiry about the decisional fitness of the 
volunteer.  
In some circumstances, a basic misunderstanding about the nature of 
clinical research can undermine the comprehension element of informed 
consent.  The mistaken belief among subjects that the principle of personal 
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care applies in the research setting has been termed the “therapeutic 
misconception.”169  In research involving healthy volunteers such as the 
AIDSVAX trials, subjects may assume that physicians will not suggest 
enrollment unless the vaccine is very likely to be of help to participants, and 
that the risks of participation are low.170  For example, the clinical trials of 
the AIDSVAX vaccine involved the use of placebos, so only half of the 
volunteers actually received the vaccine.  If the vaccine had actually been 
effective, then half of the participants had no chance of benefiting from the 
vaccine. In this case, because the vaccine was shown to be ineffective, none 
of the study participants received any health benefits from the vaccine trials.  
Therefore, it is important for volunteers to understand that clinical trials do 
not constitute a form of treatment.   
The recruitment practices employed in Thailand were one factor that 
likely contributed to the therapeutic misconception among Thai participants.  
Drug treatment differs from medical treatment in certain respects, but the 
therapeutic misconception may be applicable to the AIDSVAX trial. 
Injection drug users who enrolled in the AIDSVAX trials were recruited 
from Bangkok narcotic treatment clinics.171  Recruiting subjects at treatment 
centers is an attractive option for researchers because it provides access to 
large numbers of potential subjects at a single site.  Clinical research is 
facilitated when the subject population is convenient, “both in terms of 
availability for recruitment and for monitoring through the course of the 
study.” 172   Initially, drug users came to know and trust the staff at Bangkok 
Metropolitan Administration (BMA) narcotic clinics, where they received 
individual benefits from the methadone treatment.  Then, other researchers 
visited these injection drug users at BMA facilities to request their 
participation in a clinical trial.  One of the reasons for the willingness of 
drug users to participate in the trials was likely the “atmosphere of trust 
between BMA staff and IDU [injection drug users].”173  As a result of their 
trust in the BMA staff, injection drug users may have agreed to participate in 
clinical research under the mistaken assumption that they would personally 
benefit from participating.  
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When subjects fail to appreciate the nature of research, they may fail 
to comprehend and clearly evaluate the risk/benefit ratio for the project to 
which they are being asked to consent.174  When the subject misunderstands 
the nature of the research, a decision to participate “raises concerns about the 
autonomy of that decision.”175  The operation of HIV vaccine clinical trials 
in Thailand illustrates the concept of therapeutic misconception in practice.  
The difficulty of obtaining truly informed consent in Thailand is related to 
the manner in which subjects are recruited, as well as the fact that the 
subjects are members of a socially vulnerable segment of the Thai 
population.  
3. Social and Political Factors in Thailand Compromised the 
Voluntariness Element of Informed Consent 
The Thai clinical trials lacked the element of voluntariness more than 
any other aspect of informed consent.  Collectively, injection drug users are 
a marginalized, socially vulnerable segment of Thai society.176  A report 
from the U.S. National Bioethics Advisory Commission (“NBAC”) on 
research with human subjects recommended that vulnerability be assessed 
on the basis of individual characteristics, rather than group membership.177  
The six categories of vulnerability proposed by NBAC included cognitive, 
institutional, deferential, medical, economic, and social.178  Injection drug 
users are often incarcerated or committed to treatment programs, and occupy 
a relatively low status in society.179  Given that nearly every category 
described by NBAC could apply to Thai injection drug users, they constitute 
a vulnerable population.180  Despite their vulnerable status, vaccine clinical 
trials follow injection drug users because they engage in many practices that 
create high risks for contracting HIV. 181   
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Negative social attitudes toward injection drug users are evidenced by 
the lack of political will to curb the spread of HIV infection among 
Thailand’s drug users.182  In contrast to other at-risk groups, such as sex 
workers and military recruits, HIV prevalence among Thailand’s injection 
drug users has never dropped.183  In fact, drug users are “projected to 
account for 30 percent of new HIV infections in Thailand by 2005, a higher 
percentage than any other group.”184  Yet many people with HIV/AIDS who 
want to recover from drug addictions find it “difficult to get access to 
treatment because of discrimination in their communities.”185   
In addition to the lack of social programs for drug users with 
HIV/AIDS in Thailand, recent political movements have been characterized 
by significant violations of the legal rights of injection drug users.  Since 
taking office in 2001, one of Prime Minister Thaksin Shinawatra’s top 
priorities has been the “prevention and suppression” of narcotic drugs, which 
has negatively impacted drug users.186  When the government campaign 
against drug use was officially launched in February 2003, it resulted in 
approximately 2,275 extrajudicial killings of drug users within the first three 
months, the “arbitrary arrest or blacklisting of several thousand more…the 
endorsement of extreme violence by government officials at the highest 
levels,” and coerced or mandatory drug treatment.187   
Thai police typically profile drug users based on factors such as 
syringe markings on their arms or attendance at methadone clinics. Those 
who meet the criteria are often arrested and forced to confess to drug-related 
crimes.188  These methods of tracking and profiling individuals can have 
negative implications for the safety of anyone associated with drug use, 
including participants in HIV vaccine trials carried out exclusively on 
injection drug users.  In an environment where the rights of individuals with 
substance abuse problems are disregarded, it seems unlikely that their 
autonomy interests would be afforded much value.  
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Thai policies that coerce drug users into treatment and rehabilitation 
through threats of arrest or death compromised the voluntariness of injection 
drug users who participated in the AIDSVAX trials.  After a group of AIDS 
researchers presented their findings at the Ninth National Conference on 
AIDS in Bangkok in July 2003, Thai police raided the researchers’ offices in 
Chiang Mai and demanded to know the location of the study participants.189  
While many Thais avoid drug treatment for fear of being identified as a drug 
user and targeted for arrest, “scores of Thais—some drug users, some not—
reported for drug treatment during the war on drugs simply because they 
perceived it was the only way to avoid arrest and possible murder.”190  Drug 
users who are able to prove their enrollment in a drug treatment program 
may be able to avoid harassment by the police.191  Given the authoritarian 
mechanisms used by the Thai government to ensure compliance with drug 
treatment programs, injection drug users were probably fearful of not 
participating in the HIV clinical trials.  Drug users who enrolled in 
government-approved vaccine clinical trials to avoid persecution by 
government officials have not freely consented to participate.   
While social and political factors contributed heavily to the lack of 
voluntariness among research participants, the prospect of free health care or 
improved access to care can create strong inducements to participate.192  For 
many Thai injection drug users, participating in research may be their only 
way to access health care.  Under these conditions, subjects may believe that 
any benefit is worth the risk, no matter how unlikely it is that participation 
will confer health benefits.193  One study of Thai trial participants concluded 
that principal motivations for enrolling in the study included HIV testing, a 
physical examination, HIV information, and altruistic reasons (e.g., to stop 
the spread of HIV).194  In addition, economic incentives also played a role in 
the subjects’ decisions to participate, given that seventy-two percent thought 
that being reimbursed for their time and travel was an incentive to 
participate.195   
                                           
189
  See id. at 39. One researcher related that the police officers “pretty much wanted to know why we 
were in touch with drug users and where they were….” Id. 
190
  Id. at 32.  
191
  Human Rights Watch interviewed a thirty-six year old man who had been injecting heroin for ten 
years: “[i]f they [the police] see me, I present a card as proof that I’m in treatment at a medical center….If 
you have an ID showing you attend treatment, you are considered a ‘patient,’ so they don’t arrest you.” Id. 
at 33. 
192
  See Lertsithichai, supra note 153, at 1255. 
193
 See Page, supra note 31, at 655 (“This is particularly true where the research involves an 
intervention aimed at HIV/AIDS or other deadly diseases”).  
194
  See Vanichseni supra note 162, at 313.  
195
  Id. at 313-14. 
128                                      PACIFIC RIM LAW & POLICY JOURNAL VOL. 15 NO. 1 
The existence of incentives does not necessarily indicate that research 
subjects are being exploited.196  While drug users may be induced to enroll 
in trials by the promise of free health services, they may be even more 
influenced by the “negative attitudes held against them by officials and 
researchers” who ran the trials, particularly the Bangkok Metropolitan 
Administration.197  The health benefits of trial participation raised questions 
about undue inducement, but the more pressing reason to question the 
voluntariness of research subjects was the coercive political environment for 
injection drug users during the vaccine trial.  If the informed consent and 
autonomy of research subjects cannot be assured amid the environment of 
persecution and coercion in Thailand, then U.S. companies should not 
conduct clinical trials in Thailand.  
B. Institutional Review Boards Failed to Adequately Protect Human 
Subjects in Thailand 
Members of the IRBs that reviewed the protocols for the AIDSVAX 
vaccine trials failed to properly consider the vulnerability of the subject 
population and the implications for informed consent.  In particular, ethical 
review committees did not question the obvious differences in the selection 
criteria used for the U.S. trials and the criteria used for the Thai trials.  When 
some or all of the subjects are vulnerable to coercion or undue influence, as 
with a population of injection drug users, IRBs should ensure that 
“additional safeguards have been included in the study to protect the rights 
and welfare of these subjects.”198   
Ethical review by an IRB located in the United States ensures that 
U.S. standards and regulations for protecting human research subjects are 
maintained when research is conducted abroad.199  It is particularly 
important for the IRB to determine “whether conducting a research study in 
a developing country, rather than in the U.S. or another industrialized 
country, is justified.”200  Determining the appropriateness of a study to be 
conducted in a developing country may be more difficult for IRBs in 
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developed countries, who are often “unfamiliar with the host country 
language, culture, social and ethical norms, level of health care, and other 
factors essential for a thorough ethical review of a clinical protocol.”201  
Researchers in developing countries have expressed concerns that U.S. IRBs 
lack familiarity with research conditions in developing countries.202  As 
ethical review has become standardized under U.S. regulations, researchers 
suggest that the content of that review often focuses on the form and 
documentation of informed consent rather than the quality and substance of 
the consent process.203  When IRB members are less familiar with the 
research conditions of clinical trials in developing countries, it is particularly 
important to scrutinize the process of informed consent. 
For international research subject to U.S. regulation, prior 
independent ethical review generally involves review by committees in the 
United States and in the country where the research will be conducted.  For 
the AIDSVAX clinical trials, IRBs in Thailand reviewed the research 
proposal.204  Review by a Thai IRB was important for taking the local 
perspective into account.  However, the infrastructure for ethical review is 
not as well-developed205 in Thailand as it is in the United States.206 
The need for additional protections for drug users correlates with their 
capacity to give valid informed consent.  It is doubtful whether voluntary 
consent can be assured, given the coercive social environment in Thailand.  
Considering the special vulnerabilities of injection drug users in Thailand, 
and the challenges of procuring valid informed consent from this population, 
IRB members should have questioned the decision to study the HIV vaccine 
exclusively in this population.  IRB members initially failed to appreciate 
the coercive social environment endured by injection drug users in Thailand, 
but the committees also failed to suspend the study upon learning of the 
unsuitable conditions.  
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V. THE UNITED STATES AND THAILAND MUST IMPLEMENT LEGISLATION TO 
ENFORCE PROTECTIONS FOR HUMAN SUBJECTS 
The compelling scientific incentives for studying HIV vaccines in 
Thai injection drug users must be balanced against the legal and ethical risks 
for the subject population. Mechanisms such as informed consent and 
prospective review by IRBs have evolved to protect human subjects of 
clinical research.207  However, laws and principles can only protect human 
subjects to the extent that they are enforced.  At the time of the AIDSVAX 
clinical trials, social and political conditions in Thailand were not conducive 
to safeguarding the rights of a study population comprised of injection drug 
users.  When there is a risk that legal and ethical protections may not 
function effectively in a particular study population, the research protocol 
must be closely scrutinized by IRBs in the host and the sponsoring countries.  
The existing system of IRB review in the United States must be strengthened 
so that research will be suspended when freely-given informed consent 
cannot be obtained in a population of research subjects.   
Unlike the United States, Thailand has not enacted formal legislation 
on human experimentation.208  Therefore, while the recommendations 
proposed here may be of interest, Thailand’s immediate goal should be to 
enact an updated version of the draft legislation that has lain dormant in 
Thailand since 1993.209  However, by examining protections currently in 
force in the United States, as well as proposed improvements to those 
protections, the Thai government can incorporate the successful aspects of 
the U.S. protections into a system appropriate for Thailand.    
A. Congress Should Extend the Common Rule to Govern All Research 
Conducted on Human Subjects 
Congress should enact laws to strengthen existing research protections 
in the United States.  In order to resolve questions about the applicability of 
the Common Rule to private research conducted by companies, Congress 
should broaden the reach of the federal regulations. 210  One possible solution 
to these questions would be to extend the application of the Common Rule to 
all research conducted on human subjects, regardless of the sponsor.  
Representatives Diana L. DeGette (D-CO) and Jim Greenwood (R-PA) 
advocated for this change when they introduced the Human Research 
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Subject Protections Act of 2002.211  The bill sought to extend federal 
protections to all research involving human subjects, including research that 
is not federally funded.212  Soon after the bill was introduced in the House, 
Senator Edward Kennedy (D-MA) introduced a similar bill in the Senate.213  
Both bills died in Committee, and while a similar bill was subsequently 
introduced, it was not enacted into law.214  
Congress should act quickly to extend the protections of the federal 
regulations to all research participants, in order to keep pace with the 
increasingly private nature of clinical research.  Even if Congress extends 
the federal regulations to all sponsors located within the United States, the 
laws would be more effective if countries such as Thailand enact similar 
legislation. 
B. Gaps in the Existing U.S. Regulations Must Be Bridged and 
Inconsistencies Should Be Harmonized 
One major structural problem with the U.S. system of protections for 
human subjects is the disconnect between the federal regulations and their 
underlying ethical foundations.  IRBs must evaluate laws, institutional 
regulations, and standards of professional practice against ethical principles 
to answer practical questions about proposed research.215  The two most 
important sources of guidance that IRBs consider are the federal regulations 
and the Belmont Report.216  Although both the federal regulations and the 
ethical principles of the Belmont Report are designed to protect human 
subjects, a gap between the two authorities has led to poor IRB 
decisionmaking in cases such as the AIDSVAX trials.  Problems arise 
because the federal regulations and ethical guidance documents do not 
directly reference each other.  For example, the Code of Federal Regulations 
barely mentions ethics, or the role that ethical principles play in protecting 
human subjects.217  The Belmont Report enumerates “ethical principles and 
applications without specifying how they relate to interpreting and applying 
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federal regulatory rules.”218  As a result, “there is a lack of national guidance 
on the…ethical requirements of providing adequate protections” for human 
subjects.219  
Greater educational training for IRB members in research ethics 
would improve the current structural problems.220  When IRB members are 
familiar with the ethical issues specific to international research, they will be 
better equipped to grapple with substantive issues, as opposed to merely 
focusing on the procedural requirements of the federal regulations. 221  The 
tendency of IRBs to focus on the documentation of informed consent 
undermines the widely accepted notion that consent is a process. 222  While 
the consent document serves as a physical representation of an exchange 
between researcher and subject, it may be more important to focus on 
whether the informed consent provisions are achievable in a given social 
context and within a particular population.  The focus of the consent process 
should be on informing and protecting participants, and not on protecting 
institutions. 223   
While the provisions of the Common Rule are nearly identical to the 
provisions of the FDA regulations, the existence of two separate sets of rules 
creates another area of inconsistency in the protections.  The proposed 
Human Research Subject Protections Act of 2002, as well as the subsequent 
Protection for Participants in Research Act of 2003, sought to harmonize the 
federal regulations.224  Both bills proposed a study of the differences 
between the two statutes, and required that differences in subsequent 
rulemaking be justified.225  Minimizing the gaps between law and ethics and 
harmonizing the federal regulations is necessary for a more efficient and 
effective administration of the laws.   
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C. Accreditation Programs Would Promote Effective Oversight of 
Research on Human Subjects 
Accreditation programs for IRBs would be a powerful tool for 
accelerating and maintaining improvement in the provision of research 
protections to participants.226  At the very least, accreditation would help to 
ensure that IRBs conduct self-assessments and address deficiencies.227 The 
Council for Certification of IRB Professionals has begun offering 
credentialing programs, which could streamline review and improve 
continuing review.228  The proposed Human Research Subject Protections 
Act of 2002 would have made accreditation of IRBs voluntary, while the 
Research Revitalization Act of 2002 would have imposed mandatory 
accreditation.229  The Institute of Medicine230 advises that accreditation is 
currently “a nascent process that will require substantial time and 
development before a meaningful assessment of its added value can be 
made.”231  
D. Reviewing Committees in the United States Need Greater Familiarity 
with the Local Context of Research Conducted Abroad 
IRBs are charged with ensuring that informed consent is obtained 
from research participants in diverse communities.  The Office for Human 
Research Protections (“OHRP”), which monitors IRBs in the United States, 
“expects the designated IRB to have knowledge of the local research 
context.”232  In the case of HIV vaccine research conducted in the United 
States and Thailand, the characteristics of the sponsor and host countries 
varied greatly.  IRBs located outside of the host country should be provided 
with basic information about economic and political realities in the host 
country.233  In the case of international clinical trials, the responsibility for 
ensuring IRB familiarity with the research context should rest with both the 
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host and sponsoring countries.  Particularly for higher-risk research, such as 
HIV vaccine trials, a consultant familiar with Thai culture should be added 
to the U.S. IRB, and it may be necessary for some IRB members to regularly 
visit the research site.234   
E. Thailand and the United States Should Engage in Mutually Beneficial 
Research Collaboration 
While many aspects of the protections for human subjects are ripe for 
improvement, collaboration between the United States and Thailand should 
continue.  Both the United States and Thailand gain valuable scientific 
knowledge from clinical trials.  Additionally, Thailand receives derivative 
benefits from the “capacity building235 of its scientists, researchers and 
health personnel, and infrastructure strengthening of laboratory and 
specimen archiving.”236  Both the CIOMS guidelines and the UNAIDS 
guidance document assert that capacity building in host countries is an 
ethical component of research.237  Capacity building in Thailand is of 
particular value because Thailand continues to host vaccine clinical trials.  
Another Phase III trial is already underway in Thailand, testing a 
combination of HIV vaccines in 16,000 volunteers.238  Unlike the VaxGen 
study239 analyzed in this Comment, which exclusively recruited injection 
drug users, the current study follows a more general population of 
volunteers.240  As a case study, the VaxGen AIDSVAX clinical trials can 
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provide useful information for planning future preventative HIV vaccine 
trials.  
VI. CONCLUSION 
If the United States and Thailand continue to collaborate in the search 
for an HIV vaccine, the protections for human subjects that exist in the 
United States must be equally robust when applied in Thailand. In the 
VaxGen clinical trials conducted in Thailand, the provision of informed 
consent and IRB review failed to provide the level of protection espoused by 
the Belmont Report and required by U.S. federal regulations.  
Given the special vulnerabilities of injection drug users in Thailand 
and the challenges of procuring valid informed consent from this population, 
IRBs should have questioned the decision to study the HIV vaccine 
exclusively in this population.  Even if IRBs initially failed to appreciate the 
coerciveness of the social environment for injection drug users in Thailand, 
the committees should have suspended the study upon learning of the 
conditions.  In the future, U.S. pharmaceutical companies conducting 
research on vulnerable populations abroad must be held to the same 
standards that apply in their home country, and steps must be taken to ensure 
that federal regulations are ethically implemented in practice.  To strengthen 
the protections for human subjects, Thailand should enact comprehensive 
national legislation, and existing legislative protections in the United States 
should be expanded to reflect the increasingly international scope of 
biomedical research.   
